ReviewInternational journal of nanomedicine2024
Nanosuspension-Based Drug Delivery Systems for Topical Applications.
Review in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 51 citations in OpenAlex.
- Development and Optimization of Sorafenib Nanosuspension By High-pressure Homogenization for Improved Oral Bioavailability.Pharmaceutical research · 2026Article
- Nanosuspension-based Ocular Therapeutics for Infection Control: Integrating Mucin Interactions and Tear Film Dynamics.AAPS PharmSciTech · 2026Review
- Efficacy of Curcumin in Neurodegenerative Diseases: From Pharmacokinetic Barriers to Advanced Delivery Systems.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Milling-Induced Chitosan-HPMC Microstructural Organisation Determines the Stability Window of Concentrated Azelaic Acid Nanosuspensions.Pharmaceutics · 2026Article
- [Oral mucosal administration].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2026Article
- Curcumin-loaded nanocarriers for dermatological applications: current advances and biomedical implications.EXCLI journal · 2026Review
- Harnessing Nanoparticles and Nanosuspensions to Combat Powdery Mildew: A Frontier in Vegetable and Fruit Protection.Journal of fungi (Basel, Switzerland) · 2025Review
- Enhanced Efinaconazole Permeation and Activity AgainstPharmaceutics · 2025Article
- Characterisation and Stabilisation Mechanisms of Azelaic Acid Nanosuspensions: Insights from a Dual Stabiliser System.Pharmaceutics · 2025Article
- Comprehensive Aerodynamic and Physicochemical Stability Evaluations of Nanocrystal-Based Dry Powder Inhalers: The Role of Mannitol and Leucine in Enhancing Performance.Pharmaceutics · 2025Article
- Nanosuspension Innovations: Expanding Horizons in Drug Delivery Techniques.Pharmaceutics · 2025Review
- Pathological Mechanisms of Radiation-Induced Lung Injury and Novel Nano-Drug Delivery Therapeutic Strategies.International journal of nanomedicine · 2025Review
- Development of Dermal Lidocaine Nanosuspension Formulation by the Wet Milling Method Using Experimental Design: In Vitro/In Vivo Evaluation.ACS omega · 2024Article
- Article
- Development of a Resveratrol Nanoformulation for the Treatment of Diabetic Retinopathy.Materials (Basel, Switzerland) · 2024Article
- Advancements and Challenges of Nanostructured Lipid Carriers for Wound Healing Applications.International journal of nanomedicine · 2024Review
- The antitumor mechanisms of glabridin and drug delivery strategies for enhancing its bioavailability.Frontiers in oncology · 2024Review
- Key Challenges, Influencing Factors, and Future Perspectives of Nanosuspensions in Enhancing Brain Drug Delivery.Current pharmaceutical design · 2024Review
- Chitosan/Alginate-Based Nanoparticles for Antibacterial Agents Delivery.International journal of nanomedicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanosuspensions have garnered recent attention as a promising strategy for mitigating the bioavailability challenges of hydrophobic drugs, particularly those characterized by poor solubility in both aqueous and organic environments. Addressing solubility issues associated with poorly water-soluble drugs has largely resolved the need to enhance drug absorption and bioavailability. As mucosal formulations and topical administration progress in the future, nanosuspension drug delivery, straightforward formulation techniques, and versatile applications will continue to be subjects of interest. Nanosuspensions have undergone extensive scrutiny in preparation for topical applications, encompassing ocular, pulmonary, and dermal usage. Among the numerous methods aimed at improving cutaneous application, nanocrystals represent a relatively recent yet profoundly intriguing approach. Despite the increasing availability of various nanosuspension products, primarily designed for oral administration, only a limited number of studies have explored skin permeability and drug accumulation in the context of nanosuspensions. Nevertheless, the scant published research unequivocally underscores the potential of this approach for enhancing cutaneous bioavailability, particularly for active ingredients with low to medium solubility. Nanocrystals exhibit increased skin adhesiveness in addition to heightened saturation solubility and dissolution rate, thereby augmenting cutaneous distribution. The article provides a comprehensive overview of nanosuspensions for topical application. The methodology employed is robust, with a well-defined experimental design; however, the limited sample size raises concerns about the generalizability of the findings. While the results demonstrate promising outcomes in terms of enhanced drug delivery, the discussion falls short of addressing certain limitations. Additionally, the references largely focus on recent studies, but a more diverse inclusion of historical perspectives could offer a more holistic view of the subject.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.